Motley Fool Asset Management LLC Sells 20,990 Shares of Alphatec Holdings, Inc. $ATEC

Motley Fool Asset Management LLC lowered its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 3.4% in the 2nd quarter, Holdings Channel.com reports. The firm owned 604,810 shares of the medical technology company’s stock after selling 20,990 shares during the quarter. Motley Fool Asset Management LLC’s holdings in Alphatec were worth $6,713,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the business. Nuveen LLC bought a new position in Alphatec during the first quarter valued at $135,874,000. Vanguard Group Inc. lifted its position in Alphatec by 0.8% during the first quarter. Vanguard Group Inc. now owns 6,014,772 shares of the medical technology company’s stock valued at $60,990,000 after purchasing an additional 45,792 shares during the last quarter. American Century Companies Inc. lifted its position in Alphatec by 16.9% during the first quarter. American Century Companies Inc. now owns 5,830,031 shares of the medical technology company’s stock valued at $59,117,000 after purchasing an additional 840,974 shares during the last quarter. Royal Bank of Canada lifted its position in Alphatec by 10.8% during the first quarter. Royal Bank of Canada now owns 3,527,939 shares of the medical technology company’s stock valued at $35,773,000 after purchasing an additional 342,656 shares during the last quarter. Finally, Cerity Partners LLC lifted its position in Alphatec by 1.6% during the first quarter. Cerity Partners LLC now owns 1,859,137 shares of the medical technology company’s stock valued at $18,852,000 after purchasing an additional 30,072 shares during the last quarter. Institutional investors own 66.35% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on ATEC shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alphatec in a research report on Tuesday, October 14th. Barclays reissued an “overweight” rating and issued a $22.00 target price (up previously from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Friday, August 1st. Wall Street Zen raised shares of Alphatec from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Alphatec in a research note on Friday. They issued an “overweight” rating and a $19.00 target price on the stock. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.25.

Insider Buying and Selling

In related news, Director Mortimer Berkowitz III sold 62,500 shares of the firm’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $15.97, for a total value of $998,125.00. Following the transaction, the director owned 618,050 shares of the company’s stock, valued at $9,870,258.50. This trade represents a 9.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Patrick Miles sold 300,000 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $15.73, for a total transaction of $4,719,000.00. Following the completion of the transaction, the chief executive officer directly owned 5,564,078 shares in the company, valued at $87,522,946.94. This represents a 5.12% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 780,575 shares of company stock worth $11,769,527 over the last ninety days. 22.80% of the stock is owned by insiders.

Alphatec Trading Up 2.9%

ATEC stock opened at $16.58 on Tuesday. The company has a market capitalization of $2.45 billion, a PE ratio of -14.67 and a beta of 1.05. Alphatec Holdings, Inc. has a 12 month low of $5.18 and a 12 month high of $16.75. The firm’s 50-day moving average is $15.18 and its 200 day moving average is $13.07. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.08. The company had revenue of $185.54 million during the quarter, compared to analysts’ expectations of $178.85 million. The company’s quarterly revenue was up 27.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.29) EPS. Alphatec has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.